Year: 2024
Type: review
Abstract: Advancements in asymmetric synthesis in recent years have led to considerable interest in the development of single enantiomers of chiral drug molecules for medicinal chemistry settings. In this review, we want to compile examples of chiral medicines approved by the FDA in the years 2022 and 2023 with an emphasis on their synthesis along with information on chiral induction as well as enantiomeric excess.
Source: RSC Advances
DOI: 10.1039/d4ra05694a
Authors: Narmatha Senkuttuvan, Boopathi Komarasamy, Rajavenkatesh Krishnamoorthy, Shuvajyoti Sarkar, Sivasankaran Dhanasekaran, Parthiban Anaikutti
Language: English
Subfield: Organic Chemistry
Field: Chemistry
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $1,042
OpenAlex ID: W4403622011